Kevin Caliendo

Bob said the policies under consideration are not intended to hit physician reimbursement; the GLOBE demonstration adjudicates manufacturer-to-government discounts directly rather than through ASP, which he read as recognition of the risk to community physicians. He expressed confidence reimbursement will not be negatively impacted through 2028.

Jim explained high OpEx growth driven by MSO income statement shape (high gross margin, high OpEx). Ex-MSOs, OpEx growth was ~5% on constant currency. MSOs bring up both gross and operating margins. Core OI growth within LRP despite transitory headwinds.

Bob reiterated strategic alternatives for businesses in other category. Jim acknowledged potential short-term dilution but emphasized long-term growth and return enhancement. MWI had 7% revenue growth in the quarter.

Jim clarified LRP raise not driven by macro changes but by historical results and future expectations. Bob emphasized years of capability building and portfolio rebalancing since 2015-2016 generic market disruption prepared them for this moment.

Jim noted GLP-1 slowdown wouldn't have major earnings impact given minimal profitability. Acknowledged they wouldn't assume same rapid growth as comps get tougher but expressed strong confidence in long-term guidance ranges.

Jim detailed: $0.14 from RCA accounting (contingent liability vs NCI), COVID headwind ~$15M vs ~$30M expected, specialty mix and biosimilar growth benefiting margins. OI growth exceeding revenue growth driven by mix improvement.

Jim confirmed guidance includes typical customer losses/gains but none material beyond the one oncology customer. COVID vaccine contribution was about half of prior year Q1.

Bob confirmed strong thesis on retina pharmaceutical pipeline growth, including biosimilars and new innovation. RCA expected to grow by adding physicians.

Samad credited rising tests-per-req, consumer panels and esoteric mix for the 2.9% rev-per-req gain.

Sam said Fresenius and Corewell margin profiles improve in H2 as ramp-up costs diminish plus normal seasonal utilization strength. Fuel costs $7-10M start now across Q2-Q4. Jim said Quest does not advocate for prior authorization; instead supports requiring lab accreditation certificates for high-complexity tests.

Sam said exchange enrollments better than expected but early days for utilization measurement. Q4 organic volume 7.9% total, 4.1% ex-Fresenius/Corewell. Revenue impact from those two partnerships less than 1%. Jim added 3% organic rev-per-rec lift from stable pricing, test-per-rec increase, and consumer mix.

Jim outlined 2026 tailwinds: Fresenius ramp, Corewell scaling, consumer channel, advanced diagnostics. Headwinds: PAMA, ACA subsidy expiration, hospital pricing pressure, Nova investment ramp.

Sam confirmed ~$0.20 modernization plus QRA expenses for the year. Most modernization costs in H2. Full-year operating margin expansion still expected.

Jim detailed <1% China direct sourcing, 80% of reagents made in U.S., most supplies under multiyear contracts. Actively moving China-sourced items to alternative suppliers.

Jim explained strike limited to BC (smaller side), affecting 1,200 employees. Only 17 of 128 patient service centers can be picketed at once. Mediator involved, expected resolution in 30-45 days.

Sam provided comprehensive bridge walkthrough. Confirmed no hidden one-timers, margin expansion expected on reported basis, no explicit weather assumption for Q1.

CFO declined to quantify the outsized-versus-strong demand distinction but confirmed the lower ~19% tax rate is durable into FY2027, deferring longer-term tax guidance to a later call. CEO offered generics normalization toward 2-3% as one data point.

Jason noted PPE is not a huge revenue/margin category. Cardinal has flexible global procurement team and would welcome more US sourcing but limited domestic supply at competitive prices. Incentives needed to make domestic PPE viable. Open and able to support such policy.

Aaron emphasized consistent market dynamics with growth driven by volume, not spread changes. Jason added higher LOE pipeline over next 3 years and a component of $7B new customer revenue contributing to generic volumes.

Jason confirmed no direct impact to above-the-line operating income from the liability classification change. The $0.05 benefit flows through below the line.

Jason emphasized 1% margin distribution model insulates from pharma tariff risk. Value proposition unchanged regardless of price level, as proven with insulin price reductions.

Jason gave detailed breakdown: 10-11% core growth ex-customer/GLP-1, strength in specialty mix, retail independent, generics volume. Back-half expects more normalized levels.

Jason confirmed GLP-1 economics unchanged. On biosimilar pricing, fixed-fee model insulates CAH from price changes, same service, same compensation.

Both executives answered fully, with Julia walking through why accession growth plus test-per-accession growth is the more intrinsic volume measure.

Adam confirmed organic volume of 1.1% impacted by one consumer genetic client's financial issues and weather. Adjusted for those two items, volume would have been over 2%, consistent with full year. Confirmed it's a one-time issue with good recovery and additional business brought in.

Adam addressed Dx margins (110 bps driven by Invitae, hospital deals initially dilutive, LaunchPad on track) but deferred 2026 specifics to February guidance. Working on AI-driven savings beyond LaunchPad to offset PAMA. No direct answer on LRP achievability.

Adam confirmed CHS meets all deal criteria: first-year accretion, cost of capital return in couple years. It's outreach business (higher margin than hospital lab operations). Increased inorganic growth target to 1.5-2.5%.

Julia confirmed the directional framework: Q2 typically strong on top line, Invitae progressing toward accretion, supporting margin expansion.

Adam declined to provide quarterly guidance but reiterated the $0.10 Q1 weather impact. Julia pointed to days impact details in supplemental materials.

Adam confirmed margin expansion expected in both segments. Invitae shifts from dilutive to accretive. Julia added underlying Dx margin was mid to high 20s ex-Invitae/weather/days.

Fred framed it as a market difference (U.S. implant market more consumer-like and slower-growing than EMEA) while claiming U.S. share gains.

Ron said Q1 value creation impact was roughly neutral on G&A (costs offset savings), with savings accelerating from Q2 through Q4. Gross profit optimization also showed early Q1 benefits expected to grow. Second question: Ron said future remeasurement gains contemplated with a range but no guarantee of additional gains, embedded in overall guidance.

Ron said some remeasurement transactions are contemplated with a range of outcomes baked into guidance, but confident gains will be lower than 2025's $0.23 impact. Stanley clarified Q4 equipment strength was from normal year-end dynamics with some manufacturer-specific promotions, not massive pull-forward.

Stanley declined to comment on any specific DSO relationship but described overall DSO relationships as good, with regional DSOs moving toward HSIC. On tariffs, noted approximately 1% inflation has been passed through successfully with manufacturer negotiations, sourcing shifts, and corporate brand alternatives.

Ron provided color on market-driven margin pressures including customer shift to value products and digital equipment pricing declines but did not fully quantify the net savings-vs-investment impact.

Stanley emphasized KKR as a strategic partner with capabilities aligned across consumables, equipment, software, specialty, and Capstone operational support.

Kenny explained Q1 FCF is seasonally negative but improved to roughly $370 million from about $1 billion a year ago, citing structural working-capital gains and holding the full-year guide.

Brian noted oral GLP-1 launch is too early to dissect share shift vs net new patients, but seeing some prior authorizations come through. Expressed strong confidence the GLP-1 category will continue to grow overall.

Britt attributed H1/H2 divergence to two factors: lapping the new strategic customer onboarded in Q2 FY2025, and prior-year held-for-sale accounting accretion from Canada-based Rexall and Well.ca divestiture.

Brian emphasized community-based care must be fairly compensated and noted nothing has been officially announced, expecting legal challenges. Expressed confidence in McKesson's ability to get fair value for services.

Brian affirmed the 12-14% long-term adjusted EPS growth rate and clarified acquisitions are subject to regulatory review with first 12-month accretion provided separately.

Britt explained 3PL is ~50% of segment revenue but <5% of AOP, so a modest revenue trim barely moved profit.